Who are ASN008's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sotagliflozin Low Dose, Sotagliflozin High Dose, GSK1838262 Extended Release Tablets, RT001.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/asn008.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ASN008 — Competitive Intelligence Brief

ASN008 (ASN008) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT1 inhibitor. Area: Diabetes.

phase 2 SGLT1 inhibitor SGLT1 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

ASN008 (ASN008) — Formation Bio, Inc.. ASN008 is a small molecule that targets the SGLT1 transporter.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ASN008 TARGET	ASN008	Formation Bio, Inc.	phase 2	SGLT1 inhibitor	SGLT1
Sotagliflozin Low Dose	Sotagliflozin Low Dose	University of California, San Diego	phase 3	SGLT1/SGLT2 inhibitor	SGLT1, SGLT2
Sotagliflozin High Dose	Sotagliflozin High Dose	University of California, San Diego	phase 3	SGLT2 inhibitor	SGLT1 and SGLT2
GSK1838262 Extended Release Tablets	GSK1838262 Extended Release Tablets	XenoPort, Inc.	phase 3	SGLT1 inhibitor	SGLT1 (sodium-glucose cotransporter 1)
RT001	RT001	Biojiva LLC	phase 3	SGLT1 and SGLT2 inhibitor	SGLT1 and SGLT2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT1 inhibitor class)

Formation Bio, Inc. · 1 drug in this class
XenoPort, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ASN008 — Competitive Intelligence Brief. https://druglandscape.com/ci/asn008. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab